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Antibiotic resistance markers were analyzed in C. trachomatis clinical isolates obtained
after ineffective therapy of urogenital chlamydiasis with fluoroquinolones and macro-
lides. Heterotypical resistance to fluoroquinolones and macrolides was detected in all
clinical isolates. No significant mutations in the target genes were detected.
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Chlamydia trachomatis serovars D-K are agents of
sexually transmitted infections. Chlamydial infec-
tion of the lower compartments of the urogenital
tract not detected and treated in time is a direct
threat to human reproductive health. Tetracycline,
macrolide, and fluoroquinolone antibiotics (AB) are
used as etiotropic therapy. However, randomized
studies of the efficiency of various protocols of AB
therapy showed that cure rate never reaches 100%
[8,12]. Relapses occur in 10-30% cases [1,6].
The main cause of inefficiency of AB therapy
in bacterial infections is drug resistance of the
agent. The appearance of C. trachomatis clinical
isolates resistant to AB in vitro was reported in
many papers [6,9,13]. Molecular markers asso-
ciated with resistance to fluoroquinolones and macro-
lides were detected in C. trachomatis [2,9]. However,
no direct relationship between drug resistance of
Chlamydia and efficiency of AB therapy was de-
tected.
Here we studied AB sensitivity in vitro in cell
culture and mutations in the target genes associated
with AB resistance in C. trachomatis clinical iso-
lates obtained after ineffective fluoroquinolone and
macrolide therapy.
MATERIALS AND METHODS
C. trachomatis clinical isolates (n=9) were derived
from cervical scrapes in women and urethral scra-
pes in men. Chlamydia were cultured in McCoy cell
cultures with cycloheximide (final concentration
1 µg/ml). Two C. trachomatis reference strains
D/UW-3/Cx and E/UW-5/Cx were a kind gift from
Dr. Eva Hjelm (Uppsala University, Sweden).
Antibiotic sensitivity was evaluated as descri-
bed previously [14]. The drug concentration at
which none chlamydial incorporations were de-
tected after one passage in McCoy cell culture in
medium with AB was taken for minimum inhibitory
concentration (MIC) of this AB. Antibiotic MIC
suppressing the formation of typical chlamydial
incorporations by at least 90% was denoted as MIC90.
The minimum bactericidal concentration (MBC)
was defined as the minimum AB concentration pre-
venting the formation of incorporations after two
passages in cell culture in a medium without AB.
Levofloxacin and ofloxacin (Hoechst), erythromy-
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cin (Roussel-Ulcaf), roxithromycin and azithro-
mycin (Sigma) were used.
Chlamydial incorporations were detected by the
method of direct immunofluorescence in prepara-
tions stained with monoclonal antibodies to C. tra-
chomatis outer membrane protein (Orion Diagnos-
tica) using Eclipse E800 fluorescent microscope
(Nikon). The morphology and location of chlamy-
dial incorporations in the cells were studied using
C1 confocal modulus (Nikon). The images were
obtained at 1-sec interval and recorded using EZ-
C1 2.0 Software (Nikon). C. trachomatis DNA was
isolated by phenol extraction. The coordinates of
C. trachomatis genome and primer areas were de-
termined (Table 1). Amplification parameters were
selected in accordance with the thermodynamic
characteristics of primers and length of the target
fragment. Amplification products were purified using
Wizard PCR Preps DNA Purification System (Pro-
mega). The amplicon nucleotide sequences were
determined on an ABI Prism Genetic Analyzer 3100
sequencer (Applied Biosystems, Hitachi) using Big
Dye TM Terminator v.3.0 Cycle Sequencing kit for
thermocyclic sequencing (Applied Biosystems). The
nucleotide and amino acid sequences of the corre-
sponding gene fragments were analyzed and com-
pared using BLAST and ClustalW software [15].
3D-simulation of C. trachomatis DNA-gyrase sub-
unit A structure was carried out using FoldRec-CC
software on the base of E. coli DNA-gyrase subunit
A structure (Protein Data Bank (http://www.rsgb.
org), identification No. lab4).
RESULTS
Heterotypical sensitivity to AB was detected in all
studied isolates: AB dose suppressing the growth of
the bulk of population always differed from the
dose completely inhibiting multiplication of the agent
(Table 2). The MIC90 value fluctuated in a narrow
range and did not surpass the corresponding value
for reference strains, while MIC values consider-
ably varied: 0.25-32.00 mg/liter for levofloxacin,
0.25-128.00 mg/liter for ofloxacin, 0.015-0.500
mg/liter for erythromycin, 0.06-2.00 mg/liter for
azithromycin, and 0.03-0.50 mg/liter for roxithro-
mycin. In some clinical isolates MIC significantly
surpassed MIC90, which impeded interpretation of
the results. For example, judging from MIC90 all
clinical isolates could be regarded as fluoroquino-
lones-sensitive, while according to MIC isolates
257, 414, and 553 could be referred to the group
of AB resistant isolates in comparison with the
reference strain (Table 2). MIC of ofloxacin and
levofloxacin for isolate 257 was 512- and 16-fold
higher than MIC of these drugs from the reference
strain, respectively. Similar results were obtained
for MIC and MIC90 for macrolides. Chlamydial growth
in the presence of AB in concentrations below
MIC90 differed significantly from the growth in the
TABLE 1. Structure of Primers Used in PCR and Coordinates of Sequences Sites of C. trachomatis Genome
ompA 5'AGGTTTCGGCGGAGATCC3' 778 901779 939
5'ACGTGAGCTGCTCTCTCATCG3'
gyrA_1 5'GGAGACAGAACTACCATGCT3' 212 388212 918
5'CCATCCCTACCGCGATGCC3'
gyrB_1 5'CTTCCCCTCTCAGATCCCT3' 213 578214 192
5'GGTGTTCGTTGCAGCCC3'
gyrA_2 5'ATGCGTCTTACGTCATTTTGG3' 756 031756 452
5'TGTAGTCATCCCTACTGCGATG3'
gyrB_2 5'AAGTGGCATCTTTGTGGCGT3' 756 772757 547
5'GGCGGAACCCATCTCG3'
23SrRNA_1 5'TATGGTGTGACGCCTGCC3' 857 790859 361
23SrRNA_2 879 837880 850
23SrRNA_1 5'CCTCCAACCTATCAACCACG3'
23SrRNA_2
dmpP 5'CGTTATGATCCCAGGATCCCT3' 857 790859 361
tktB 5'CCCAATATAGAACCGAAAATTCGA3' 879 837881 378
Note. *Identification No. in GenBank of the studied genes nucleotide sequences: NC_000117. **Numeration for complete sequence of
C. trachomatis D/UW-3/Cx genome.
DNA locus Coordinates**Nucleotide sequence*
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presence of AB in concentrations ranging from
MIC90 to MIC (Fig. 1). In the presence of AB in a
concentration below MIC90, the number of infected
cells in the monolayer 48 h after infection was >50%;
typical chlamydial incorporations were well dis-
cernible in the cells (large, bulky, shifting the cell
nuclei, and containing mature elementary bodies;
Fig. 1, a, d, e, g). In contrast, after culturing in the
presence of AB in concentrations from MIC90 to
MIC only solitary chlamydial incorporations with
atypical morphology were detected (Fig. 1, b, c, f,
h). MIC was higher than MBC for virtually all isol-
ates, that is, atypical incorporations not always con-
tained mature elementary bodies with infective
activity. R. B. Jones et al., who for the first time
described a phenomenon when a small part of chla-
mydial population survived in the presence of high
AB concentrations, called it “heterotypical resist-
ance” [6]. Thus, heterotypical resistance to macro-
lides and fluoroquinolones was detected in all cli-
nical isolates.
Analysis of QRDR gyrA, gyrB, parC, and parE
sequences showed no differences from the structure
of analogous sites in the published C. trachomatis
sequence (Gen Bank, No. NC_000117) in any of
the isolates. Some isolates had 2 mutations in the
QRDR neighboring gyrA region: Val60→Ala
(GTA→GCA) and His129→Gln (GAC→GAG).
Amino acid substitutions in the QRDR region in
fluoroquinolone-resistant microorganisms between
topoisomerase amino acid residues 67 and 106 were
previously detected (substitutions on Ser83 and Asp87
hot points were most incident) [2]. 3D-modeling of
C. trachomatis DNA gyrase subunit A showed re-
mote spatial location of amino acid residues 60 and
129 in comparison with location of the known “hot
points” (Fig. 2). Mutations were detected only in
clinical isolates belonging to genotype E with dif-
ferent ofloxacin and levofloxacin MIC values; no
mutations of this kind were detected in isolates with
genotypes H and G. It is most likely that the iden-
tified substitutions are manifestations of gyrA gene
polymorphism, specific of genotype E.
No differences were detected in any of genes
23SrRNA_1 and 23SrRNA_2 sites corresponding to
23S rRNA V-domain, in which macrolide resist-
ance-associated mutations are located [9]. Hence,
the detected heterotypical fluoroquinolone and ma-
crolide resistance of clinical isolates is not deter-
mined by mutations in the target genes associated
with AB resistance.
However, heterotypical AB resistance of Chla-
mydia is the main cause of ineffective AB therapy
of chlamydial infection. Antibiotic therapy is effec-
tive, if correct AB dose is calculated with conside-TA
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ration for MIC. MIC of AB for obligate intracellular
bacteria is a variable depending primarily on the
type of cells in which the agent multiplies. This is
clearly demonstrated by MIC of azithromycin in
vitro [14], which is different for C. trachomatis
serovar D in different cell cultures: 1 µg/ml for
BGMK, 0.125 µg/ml for McCoy, 0.016 µg/ml for
Hela, and 0.008 µg/ml for HL cells.
!
ba c
d e f
g h
MIC of AB directly depends on the time of AB
penetration into the cells (before or after infection).
This is confirmed by the results of in vitro experi-
ments: fluoroquinolones in a concentration of 64
µg/ml do not inhibit the formation of chlamydial
bodies if they are added 20 h after infection [10];
MIC of macrolides, fluoroquinolones, and tetra-
cyclines drastically increase if these AB are added
8 h after infection [14]. In turn, according to phar-
Fig. 1. Growth of C. trachomatis in McCoy
cell culture with AB 48 h after infection. a-c)
isolate 257; d-f) isolate 534; azithromycin
concentrations (mg/liter): a) 0.03; b) 0.5; d)
1.0; ofloxacin concentrations (mg/liter): d)
0.03; e) 0.06; f) 0.5. g, h) isolate 104,
levofloxacin; g) typical incorporation; h)
atypical incorporation. Arrows show C. tra-
chomatis incorporation. Staining by fluores-
cein-labeled monoclonal antibodies, ×40 (a-f),
×60 (g, h).
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macokinetic regularities, active concentration of AB
is different in the blood and tissues and changes
with time. Heterotypical resistance is an additional
factor, contributing to AB inefficiency, if its con-
centration is higher than the minimum tolerated
concentration, but lower than MIC.
Analysis of growth and morphology of chla-
mydial inclusions in the presence of AB suggests
that heterotypical resistance is a manifestation of
transition of a part of the agent population into a
persistent state under the effect of certain AB doses.
Persistence of Chlamydia is a part of vital cycle of
these microorganisms, it can be easily reproduced
in cell culture under the effects of some factors,
including AB [4]. Azithromycin, ciprofloxacin, and
ofloxacin are inductors of Chlamydia persistence,
they interrupt the productive intracellular cycle of
Chlamydia, the microorganisms stop active multi-
plication, but retain metabolic activity, which is
seen from negative result of cultural study and de-
tection of short-living rRNA transcripts [3,4].
Hence, the inefficiency of AB therapy is not
caused by the formation of AB resistant forms of
Chlamydia leading to significant mutations in tar-
get genes. Inefficiency of AB therapy can be cau-
sed by improperly selected AB dose and failure of
effective control of heterotypically resistanct agent
and by transition of the agent into a persistent state
under the effect of AB.
The authors are grateful to I. Yu. Torshin for
his assistance in the creation of a 3D-model of C.
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Fig. 2. 3D-model of C. trachomatis DNA gyrase subunit A structure.
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